Methylene blue Oral, Intravenous and Reglan
Determining the interaction of Methylene blue Oral, Intravenous and Reglan and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using metoclopramide together with methylene blue may occasionally cause high blood pressure and high fever. It may be preferable to wait at least 14 days after you are off methylene blue before you start using metoclopramide. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek immediate medical attention if you experience sudden and severe headache, blurred vision, confusion, seizures, chest pain, nausea or vomiting, sudden numbness or weakness (especially on one side of the body), speech difficulties, fever, sweating, lightheadedness, and/or fainting during treatment with these medications, as these may be signs and symptoms of excessively high blood pressure. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Theoretically, metoclopramide may precipitate severe hypertensive reactions and hyperpyrexia in patients treated with monoamine oxidase inhibitors (MAOIs). Metoclopramide has been shown to induce the release of catecholamines in patients with essential hypertension. This action could produce a synergistic sympathomimetic effect with MAOIs, which enhance norepinephrine storage in adrenergic neurons.
MANAGEMENT: While clinical data are lacking, metoclopramide should preferably not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with metoclopramide.
- "Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
- Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984): 548-9
Generic Name: methylene blue
Brand name: ProvayBlue, Urolene Blue
Synonyms: Methylene blue (injection), Methylene Blue
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Methylene blue Oral, Intravenous-Reglan (Metoclopramide Injection Solution)
- Methylene blue Oral, Intravenous-Reglan (Metoclopramide Tablets)
- Methylene blue Oral, Intravenous-Reglan Intravenous
- Methylene blue Oral, Intravenous-Reglan Tablets
- Methylene blue Oral, Intravenous-Regonol
- Methylene blue Oral, Intravenous-Regorafenib
- Reglan-Methylergonovine
- Reglan-Methylergonovine Injection
- Reglan-Methylergonovine Maleate Injection
- Reglan-Methylergonovine Maleate Tablets
- Reglan-Methylergonovine oral and injection
- Reglan-Methylergonovine Tablets